MNKYPOX Mpox (Monkeypox) clade 1b International Emergency Thread

phloydius

Veteran Member
1725808713498.png

Monkeypoxtally
@Monkeypoxtally
JUST IN: Australia records 10 new Mpox cases in the last 24 hours, bringing the total number of cases in the country to 473 in 2024.
5:41 PM · Sep 7, 2024

Monkeypoxtally
@Monkeypoxtally
Mpox cases in Australia are escalating rapidly. In just the past 35 days, there have been more cases than the previous two years combined.
6:24 PM · Sep 7, 2024

KESSEF
@kessef212
I think Australia is conducting mass testing compared to Western countries, where there is almost no testing.
6:27 PM · Sep 7, 2024

Monkeypoxtally
@Monkeypoxtally
Agreed, which is a big problem in curbing the virus. If Australia have on average 20 cases a day, the U.S. should have over 200 cases a day.
6:29 PM · Sep 7, 2024
 

phloydius

Veteran Member
Translation from Google below:
Article is from Sep 6, 2024.

------------

Relatives claimed the body of an Argentine infected with mpox who died in Playa del Carmen

Santiago Molina had been diagnosed with monkeypox, from which he recovered two weeks ago, however, he died in recent days due to respiratory failure.

Estados | 06/09/2024
Adriana Varillas | Ver perfil

Cancún.- The body of citizen Santiago Molina, originally from Argentina, was claimed by his relatives and taken to his country.

Molina had been diagnosed with monkeypox or mpox, from which he recovered two weeks ago according to the Quintana Roo Health Secretariat (Sesa).

However, he died in recent days due to respiratory failure at the General Hospital of Playa del Carmen, in the municipality of Solidaridad.

This Friday morning, his relatives showed up at the hospital and took the body of the 28-year-old young man to fly to Argentina, the state agency reported.
 

jward

passin' thru
chinadaily.com.cn


Chinese mpox vaccine to undergo clinical trial​


王丹宁

~3 minutes



66df9b02a3103711c3480159.jpeg
[Photo/IC]
The country's top drug regulator has cleared a mpox vaccine developed by Chinese drugmaker Sinopharm for clinical trial on Monday, which could be the nation's first experimental dose to battle the deadly disease, according to the company.

The domestic vaccine candidate, created by the Shanghai Institute of Biological Products and administered by Sinopharm, is expected to play an important role in preventing and controlling mpox infections, the company said in a statement released on Monday afternoon.

In China, a vaccine candidate typically goes through three phases of clinical trials before gaining market approval. The process can take years, even decades, but the National Medical Products Administration, China's top drug regulator, has launched a number of accelerated or streamlined channels to facilitate applications of novel drugs and vaccines or those in urgent need.

According to the company, the new vaccine is a replication-deficient vaccine based on a strain called MVA. The description is the same as Jynneos, the world's first mpox vaccine approved by the Food and Drug Administration in the United States in 2019.

The company said that it has accumulated rich data on the vaccine's safety and efficacy through preclinical studies and production methods for the vaccine that are deemed reliable and stable.

"In nonhuman primate models, the vaccine can generate good immune protection against the mpox virus," it said.

There is currently no approved mpox vaccine in China. Globally, a few vaccines have been approved in the United States, Canada, the European Union, Japan and Russia.

The World Health Organization said on Aug 14 that the mpox outbreak in Africa constitutes a public health emergency of international concern — its highest form of alert.

Previously, in July 2022, the WHO declared a global emergency but then lifted it in May last year because of a sustained decline in international cases.

So far, more than 120 countries and regions across the world have reported more than 100,000 confirmed infections and 226 related deaths.

China classified mpox as a Class B infectious disease — on par with COVID-19 and HIV/AIDS — in September last year.

The nation reported the first imported case in September 2022 and the first domestic case in June last year.

By the end of July, the nation had reported 2,567 confirmed cases.

 

helen

Panic Sex Lady
Too many words.

Here is the plan: send pox swabs off to a designated lab to test for clade TWO.

If swab tests negative for clade TWO, send swab to the CDC lab to test for clade ONE.

WHERE IS THE VECTOR during the time the swabs are touring the country?



FACT SHEET: United States Response to the Clade I Mpox Outbreak in Several African Countries


FACT SHEET: United States Response to the Clade I Mpox Outbreak in Several African Countries
www.cdc.gov
On August 14, 2024, the World Health Organization (WHO) declared a Public Health Emergency of International Concern about the upsurge of mpox cases in the Democratic Republic of the Congo (DRC) and a growing number of countries in Africa. This announcement followed the Africa Centres for Disease Control and Prevention's (Africa CDC) declaration of a Public Health Emergency of Continental Security on August 13. The significant increase of clade I mpox cases, in both endemic countries (those that have previously had mpox outbreaks) and non-endemic countries (those that have historically not reported mpox outbreaks), threatens the health security of the region, as well as countries outside Africa. In addition, clade I mpox has a newer sub-clade referred to as clade Ib. Both clade Ia and clade Ib are circulating in DRC and have been detected in neighboring countries and in Sweden and Thailand (one case each associated with travel to Africa with known clade I cases).

In 2022, the world experienced a global outbreak of clade IIb mpox, which led to more than 95,000 cases across 115 non-endemic countries and continues to occur in the United States. The Biden-Harris Administration responded by ensuring the JYNNEOS mpox vaccine was available to at-risk populations in the U.S.

In February, as the clade I mpox outbreak grew in DRC, the Biden-Harris Administration established an incident response structure across federal departments and agencies to ensure a coordinated response and to take a proactive approach to U.S. domestic preparedness for potential clade I mpox cases. Clade I mpox causes a higher number of severe infections and has a higher mortality rate than clade IIb mpox. Because evidence for clade I mpox clinical outcomes is based primarily on data from endemic countries without widespread supportive care, particularly DRC, we do not yet know how clade I mpox would impact Americans; we do expect it would cause lower morbidity and mortality in the United States.

United States preparedness for clade I mpox

The Biden-Harris Administration has been closely monitoring the spread of mpox, specifically clade I mpox, and has been working since December 2023 to prepare domestically. The risk to most Americans from clade I mpox circulating in Central and Eastern Africa and the travel associated cases outside of Africa is very low, and there are no known cases in the United States at this time. The United States is well prepared to rapidly detect, contain, and manage clade I cases should they occur domestically.

The United States continues to increase our capacity to detect cases of clade I and clade IIb mpox through existing surveillance systems, including wastewater testing, and through expanding the robust diagnostic testing capacity built during the ongoing clade IIb outbreak to ensure coverage for clade I. The ability to expedite such diagnostic testing—in particular for those with recent travel to DRC or neighboring countries—also supports rapid detection. In addition to reaffirming the importance of mpox vaccination for those who are eligible, we are working to prevent the spread of both clades of mpox by providing and disseminating recommendations for clinicians, health departments, diagnostic laboratories, and the public.

From August 2022 to August 2024, the Administration for Strategic Preparedness and Response (ASPR), part of the Department of Health and Human Services (HHS), distributed more than one million vials of the JYNNEOS vaccine across the United States to mitigate the spread and severity of the clade II mpox outbreak. In addition to the preventive vaccine, partners across the U.S. government are working to better understand the effectiveness of existing treatments for mpox and have treatment options available in the event that clade I mpox is reported in the United States. The United States will continue to provide information to the public on transmission, prevention, and treatment of mpox. Those who have already had clade IIb mpox or who are fully vaccinated against it are expected to be protected against clade I mpox.

CDC has issued an updated Health Alert Network advisory for clinicians and public health departments and partners, as well as an updated Travel Health Notice, recommending travelers to DRC and neighboring countries to practice enhanced precautions. Through the State Department, our embassies are working to keep U.S. citizens abroad informed of these updates. At this time, CDC and WHO do not discourage travel to DRC or elsewhere due to the mpox outbreaks.

United States support to the global mpox outbreak


The U.S. government has been closely monitoring the spread of clade I mpox in DRC and the risk to neighboring countries since 2023, and we have been working closely with the affected country governments and regional and global health partners to reduce the impact of this outbreak and safeguard public health. The U.S. government support for the mpox response builds on our longstanding partnerships in global health security and development with DRC and throughout Africa, which have helped to combat infectious diseases, such as HIV, tuberculosis, and malaria for more than 20 years. In fiscal year 2023, the United States allocated more than $2.65 billion in bilateral health funding to countries in Central and Eastern Africa and is the largest global health donor.

Since March 2024, USAID and CDC together have provided an additional $20 million USD to support clade I mpox response efforts in Central and Eastern Africa, and on August 20, USAID announced up to an additional $35 million in emergency health assistance to bolster response efforts, pending Congressional Notification, bringing the proposed total U.S. government financial support for DRC and other affected countries in the region to more than $55 million.

In addition to direct financial support, the United States government is surging staff to support the mpox response. More than 200 staff including epidemiologists, laboratorians, and risk communication experts have been deployed to support response efforts in the United States and Africa. United States government support has focused on a range of critical public health interventions aimed at limiting transmission and reducing mpox morbidity and mortality. These interventions include surveillance with deployment of additional local field epidemiologists, risk communication and community engagement, laboratory supplies and diagnostics, infection prevention and control, clinical services, and vaccine planning.

In addition to scaling up surveillance, testing, and treatment of cases, vaccination will be a critical element of the response to this outbreak. Successful vaccination campaigns will require health workers to provide vaccinations, financial support to roll out vaccine and vaccination supplies, and regulatory approval for use of vaccines in affected countries. To support this effort, USAID is donating 50,000 doses of the FDA-approved JYNNEOS vaccine to DRC, as well as financial support for rollout of the vaccine doses. The United States is working with other countries that have vaccine stockpiles, WHO, and international partners to encourage additional donations that support vaccine efforts and address challenges with vaccine delivery. This includes evaluating vaccine demand, supporting country engagement on regulatory pathways, planning vaccine implementation, and providing technical assistance to deliver the vaccines.

The United States is working with bilateral, multilateral, and private sector partners to develop and implement a coordinated response – including encouraging collaboration between WHO and Africa CDC on their response plans. The United States, through the State Department, will continue working through the U.S.-Africa CDC Joint Action Plan adopted in November 2023 to increase African Union Member States' capacity to prevent, detect, and respond to health emergencies.

The Biden-Harris Administration will continue its whole-of-government response to this growing outbreak, building on lessons learned from the 2022 mpox response. To learn more about mpox, signs and symptoms, treatments, and prevention, please visit the CDC website here.
 

mudlogger

Veteran Member
Today is my expiration date.
Okay.

Two things can make me cry...Jesus stories in people's lives, and stories of self-sacrifice.

By getting vaxxed, you signed a blank check for the benefit of those who depend on you.
It was a very honorable action and you are being used by Him in ways you don't see.

When I joined the Navy, lo those 40 years ago, I didn't realize I was signing a blank check
with my life...I just wanted out of west Texas. It was a selfish action, but it was used by Him.

Quit thinking this is your expiration date.

You, and all of us, are here for HIS purpose.

Every breath we take is by His will.

Look at your daily life through those lenses, and be amazed at what you see.

Lalu, which is what we say at our house for 'love you.'
 

helen

Panic Sex Lady
Confirmed cases = 8

Deaths have to be in confirmed cases = 2

Minimum 25% lethal as of right now. If all of the other confirmed and suspected cases survive, the lethal rate is 4%. In other words, bad enough.


Cases of the mpox virus have killed two people in Cameroon since April with six further and 40 other suspected cases, the health ministry said Wednesday.

 

helen

Panic Sex Lady
Posted only to point out the fifth confirmed mpox patient in Pakistan returned from Saudi Arabia - Mecca, I'm guessing.



According to sources, the 33-year-old patient traveled from a Gulf country and arrived in Pakistan via Islamabad Airport on September 7. The patient then traveled to Peshawar, staying at a hotel.

The following day, he visited a private clinic for treatment and was subsequently referred to Khyber Teaching Hospital, where his condition came to light.

Samples were taken from the patient and sent to the Public Health Reference Lab, where the presence of the Mpox virus was confirmed. The patient has been quarantined at his home in Lower Dir. It is reported that after arriving from Saudi Arabia, the patient had no contact with any relatives and only interacted with passengers on the flight.

Surveillance of the patient is being carried out under the supervision of the district health officer (DHO) in Lower Dir, and the patient's symptoms are improving. His family has been informed about precautions to prevent the spread of infection.

K-P Health Minister Qasim Ali Shah expressed regret over the poor screening system at Islamabad Airport. He questioned how a patient with mpox could leave the country's largest airport without being screened. He raised concerns that many such patients could be traveling to different regions of the country from Islamabad Airport daily.

Fifth case of mpox virus confirmed in K-P | The Express Tribune
 

John Deere Girl

Veteran Member
Posted only to point out the fifth confirmed mpox patient in Pakistan returned from Saudi Arabia - Mecca, I'm guessing.



According to sources, the 33-year-old patient traveled from a Gulf country and arrived in Pakistan via Islamabad Airport on September 7. The patient then traveled to Peshawar, staying at a hotel.

The following day, he visited a private clinic for treatment and was subsequently referred to Khyber Teaching Hospital, where his condition came to light.

Samples were taken from the patient and sent to the Public Health Reference Lab, where the presence of the Mpox virus was confirmed. The patient has been quarantined at his home in Lower Dir. It is reported that after arriving from Saudi Arabia, the patient had no contact with any relatives and only interacted with passengers on the flight.

Surveillance of the patient is being carried out under the supervision of the district health officer (DHO) in Lower Dir, and the patient's symptoms are improving. His family has been informed about precautions to prevent the spread of infection.

K-P Health Minister Qasim Ali Shah expressed regret over the poor screening system at Islamabad Airport. He questioned how a patient with mpox could leave the country's largest airport without being screened. He raised concerns that many such patients could be traveling to different regions of the country from Islamabad Airport daily.

Fifth case of mpox virus confirmed in K-P | The Express Tribune
I feel so much better knowing he had no contact with his family, he only interacted with passengers on his flight...passengers who God only knows where they are now or if they've managed to spread mpox all over the globe. SMH
 

helen

Panic Sex Lady
I feel so much better knowing he had no contact with his family, he only interacted with passengers on his flight...passengers who God only knows where they are now or if they've managed to spread mpox all over the globe. SMH
Mecca. I think you have to be nekkid under the white robe when you go in to the Kabbah.
 

Housecarl

On TB every waking moment
Hummmm.........I've got to wonder what else would end up in those shots?........

Posted for fair use......


Rich nations have millions of mpox shots: Will they share with Africa?​

By Jennifer Rigby and Julie Steenhuysen
September 12, 2024 8:41 PM PDT Updated 40 min ago

  • Summary
  • Companies
  • Fewer than 4 million doses pledged out of needed 18-22 million
  • New strain has spread to 14 African countries
  • High vaccine prices, slow regulatory procedures hinder response
Sept 12 (Reuters) - Rich countries have several hundred million doses of vaccines that could help fight an mpox outbreak in Africa, where donated shots fall far short of what is needed, according to a Reuters tally of public statements, documents and estimates from non-governmental organizations.

The shots have been stockpiled for years by countries such as Japan, the United States and Canada in case smallpox, an eradicated disease that is the more dangerous cousin of mpox, ever makes a comeback. Some of the vaccines were used outside of Africa in 2022 when mpox spread globally.

A small fraction of those doses could help curb what is now the biggest mpox outbreak on record in the Democratic Republic of Congo and neighboring countries, disease experts say.

Fewer than 4 million doses have been pledged for donation out of an estimated 18 million to 22 million that are needed to vaccinate 10 million people in the next six months, depending on the vaccine, Africa's Centers for Disease Control and Prevention said in a statement.

"It's not a technical question, it's a political one," Maria Van Kerkhove, acting head of pandemic and epidemic prevention at the World Health Organization, told Reuters. She is lobbying for more donations alongside Africa's CDC and other health authorities.

"Vaccines are useless on shelves," Van Kerkhove said. "Why wouldn't we get them to the people who need them right now?"

The current outbreak began in early 2023 in Congo, which accounts for most of the 37,500 infections and 1,451 deaths. It has spread to 14 African countries, according to Africa's CDC. A first inoculation campaign using 265,000 donated shots is due to begin in Congo in early October.

"If we'd had more doses earlier, we could have planned a large-scale campaign and reduced transmission," said Cris Kacita, head of Congo's mpox response.

Health officials are concerned about a new strain, known as clade Ib, which was first identified in Congo and appears to spread more easily by close contact. Children are particularly vulnerable to mpox, as well as people with immune system conditions like HIV. The risk outside of Africa appears low at this time.

"Children are the main victims of this epidemic. The first emergency is not really being treated," Kacita said.

Other factors have held back the mpox response, including slow regulatory procedures at WHO and in Congo, high vaccine prices and competing health crises exacerbated by conflict in the country.

Mpox shots alone are not a magic bullet and affected countries also need access to testing and awareness-raising to tackle outbreaks effectively, disease experts say.

But the stark divide on vaccine access shows governments are still not prepared to stamp out viral threats where they begin and before they spread.

"The disinterest in mpox and other viral threats where they emerge is a significant danger to people the world over," said Peter Maybarduk, access to medicines director at the U.S. consumer group Public Citizen.

WHERE ARE THE DOSES?Three vaccines recommended by the WHO are held in stockpiles worldwide: Bavarian Nordic's (BAVA.CO), opens new tab Jynneos (Imvanex or Imvamune outside the United States); KM Biologics' LC16; and Emergent BioSolutions' (EBS.N), opens new tab ACAM2000.

They are all being considered for purchase and donation in Africa, said a spokesperson for Gavi, the Vaccine Alliance, a global group that helps lower-income countries buy vaccines. The group has up to $500 million available for the mpox response.Many wealthy countries declined to say how much vaccine they have, citing national security reasons.

Japan has around 200 million doses of LC16, according to a WHO document, opens new tab from 2022. Unlike rival shots, LC16 can be used for children, although it is not available outside of Japan and requires special needles to administer.

Kacita said Congo is in discussions for up to 3.5 million LC16 doses from Japan.

KM Biologics declined to comment. A Japanese health official said Congo had asked for 3.05 million doses, but would not confirm the timing of the delivery. He said the WHO's 200 million figure was not correct but would not confirm the size of the national stockpile.

Canada may have up to 2 million doses from Bavarian Nordic in its stockpile, said Adam Houston, medical policy and advocacy adviser for Medecins Sans Frontieres Canada, based on previous years’ announcements from the company.
This shot was used to curb the 2022 mpox outbreak outside of Africa. This week, the Canadian government said it would donate up to 200,000 doses.

U.S. officials declined to disclose how much vaccine is in its stockpile, but two senior Biden administration officials said it is enough to protect its population.

That includes around 100 million doses of Emergent's vaccine, according to Maybarduk, as well as an unspecified number of Jynneos shots, which experts say have fewer side effects. The U.S. has donated 60,000 Jynneos doses to the current outbreak.

Spain is among the largest confirmed donors, pledging in August 20% of its mpox vaccine stockpile, or 500,000 doses. The country has urged all European Union member states do the same.

The European Commission has a joint procurement contract with Bavarian Nordic to buy vaccines for donations, and has sent 215,000 doses to Congo.

"Some of the vaccines could cost around $150 for a person to be fully vaccinated, a price that is unaffordable to most African countries," a spokesperson for the Africa CDC team in DRC said. "So donated vaccines from countries is all the more important."

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Reporting by Jennifer Rigby in London and Julie Steenhuysen in Chicago; Additional reporting by Sonia Rolley, Anna Mehler Paperny in Toronto, Rocky Swift in Tokyo, Christian Kraemer in Berlin, Inti Landauro in Madrid, Maggie Fick in London, Gleb Bryanski, Niklas Pollard in Stockholm, Louise Rasmussen in Copenhagen, Lefteris Papadimas in Athens, Jihoon Lee in Seoul; Editing by Michele Gershberg and Bill Berkrot
 

helen

Panic Sex Lady
Closer, ever closer.

Nine whole days? Are we in a hurry?



Mexico grants health registration to monkeypox vaccine | Jankari News


Mexico grants health registration to monkeypox vaccine
www.jankarinews.com

(CNN Spanish) – The Government of Mexico reported this Thursday that it granted health registration for the vaccine against monkeypox (mpox) to the company Bavarian Nordic
.


The Federal Commission for the Protection against Health Risks (Cofepris) indicated in a statement that this took nine days for the technical and scientific review, so that the biological agent to prevent the disease can be marketed and applied under medical surveillance.


“The vaccine, which can be used for primary vaccination or revaccination, is indicated exclusively for adults aged 18 years and older with a high risk of exposure to the virus. Its use is not recommended in the general population, including children, pregnant or breastfeeding women,” he explained. She added that people with untreated HIV, other sexually transmitted infections, or conditions that weaken the immune system due to cancer treatments or immunosuppressants are at higher risk of complications.


Monkeypox can cause painful skin rashes on the face, palms of the hands, and soles of the feet. It is primarily transmitted from person to person through direct contact with skin lesions, scabs, contaminated body fluids, or through respiratory droplets. Its symptoms can begin five to 21 days after exposure and include headache, fever greater than or equal to 38° C, rash or skin lesions, back pain, enlargement or pain of lymph nodes and muscle pain, he explained.


This year, as of August 5, authorities report 49 confirmed cases of monkeypox in Mexico.


The World Health Organization (WHO) declared on August 14 that the monkeypox outbreak in Africa constitutes a global health emergency.
Source link
 

Heliobas Disciple

TB Fanatic
(fair use applies)


WHO Pre-Qualifies First Mpox Vaccine, Recommends Single Dose and ‘Off-Label’ Use for Children

Kerry Cullinan
13/09/2024

Bavarian Nordic’s MVA-BN vaccine, has become the first mpox vaccine to be added to the World Health Organization (WHO) prequalification (PQ) list, enabling its use globally.

The WHO has also recommended that single doses be given in supply-constrained outbreak situations instead of the usual two doses, and “off label” use for children as the vaccine is not yet approved for under-18s.

WHO Prequalification (PQ) and Emergency Use Listing (EUL) are mechanisms used to evaluate quality, safety and efficacy of medical products, such as vaccines, diagnostics and medicines, and product suitability for use in low- and middle-income countries.

“PQ is based on the review of full set of quality, safety and efficacy data on medical products, including risk management plan and programmatic suitability,” according to a Friday media release from WHO.

“WHO’s assessment for prequalification is based on information submitted by the manufacturer, Bavarian Nordic, and review by the European Medicines Agency, the regulatory agency of record for this vaccine,” the WHO added.

A month ago, WHO Director General Dr Tedros Adhanom Ghebreyesus declared mpox a public health emergency of international concern (PHEIC) as the outbreak intensified in the Democratic Republic of the Congo (DRC) and neighbouring countries.

Since the global outbreak in 2022, over 120 countries have confirmed more than 103 000 cases.

This year, there have been 25 237 suspected and confirmed cases and 723 deaths from different outbreaks in 14 African countries (8 September 2024). Morocco reported its first case on Thursday.


‘Off label’ for children


“This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future,” said Tedros.

“We now need urgent scale up in procurement, donations and rollout to ensure equitable access to vaccines where they are needed most, alongside other public health tools, to prevent infections, stop transmission and save lives.”

The MVA-BN vaccine (marketed as Jynneous and Imvamune) is administered in people over the age of 18 as a two-dose injection given four weeks apart. After prior cold storage, the vaccine can be kept at 2–8°C for up to eight weeks.

Although, MVA-BN is not yet registered for use in children, the WHO’s head of Research and Development, Dr Ana-Maria Restrepo, told a recent media briefing that the DRC could use the vaccine “off label” for children, and that there were a number of studies – including clinical studies – that had established its efficacy in children. The majority of mpox cases in DRC are in children.

The WHO also noted that it could be used “off-label” for pregnant and immuno-compromised people “in outbreak settings where the benefits of vaccination outweigh the potential risks”.

WHO has also recommended single-dose use in supply-constrained outbreak situations. Available data shows that a single-dose MVA-BN vaccine given before exposure has an estimated 76% effectiveness whereas the two-dose schedule offers an estimated 82% protection.


Help for national regulators


“The WHO prequalification of the MVA-BN vaccine will help accelerate ongoing procurement of the mpox vaccines by governments and international agencies such as Gavi and Unicef to help communities on the frontlines of the ongoing emergency in Africa and beyond,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products.

“The decision can also help national regulatory authorities to fast-track approvals, ultimately increasing access to quality-assured mpox vaccine products,” he added.

The WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization reviewed all available evidence and recommended the use of MVA-BN vaccine in mpox outbreaks for people “at high risk of exposure”.

Bavarian Nordic CEO Paul Chaplin said that his company is “highly encouraged” by the PQ, “which is a testament to the strengths of our vaccine and the quality of data we have generated through numerous studies, as well as in real life”.


Company aims for two million doses in 2024

“Bavarian Nordic has recently filed a submission to the European Medicines Agency to extend the approval to adolescents 12-17 years of age and is also working with partners, including the Coalition for Epidemic Preparedness Innovations (CEPI) to evaluate the safety and efficacy of the vaccine in children 2-12 years of age,” according to a company statement.

“While we continue to work with WHO and other regulatory bodies to expand the approval to include children, who are severely impacted by the mpox outbreak, we are pleased that this approval will help accelerate access to our vaccine for communities across the entire African continent and we applaud the WHO for their swift review and action to make this happen,” added Chaplin.

Bavarian Nordic has undertaken to focus its production efforts on MVA-BN, which will enable it to produce two million doses by the end of the year, and potentially 13 million by the end of 2025, the company reported on Thursday.

Dr Rogerio Gaspar, WHO Director for Regulation and Prequalification, said the global body was “progressing with prequalification and emergency use listing procedures with manufacturers of two other mpox vaccines: LC-16 and ACAM2000. We have also received six expressions of interest for mpox diagnostic products for emergency use listing so far”.

The LC-16 vaccine, produced by Japan’s KM Biologics, is licensed for use in children.
 

Heliobas Disciple

TB Fanatic
(fair use applies)

EMPHASIS IN ORIGINAL (not mine)


Nobody was willing to believe me
Radagast
September 14, 2024

Let’s go back in time for a moment, shall we?

Two years ago I told you:

-Monkeypox is not a “gay STD”. Gay men are just a stepping stone, for this virus to spread into the general population. They forced me to delete this comment on Twitter. I explained that it seems the virus started spreading because the population suffers a mild degree of immunodeficiency, as there were multiple divergent strains suddenly spreading around the world.

-Vaccines are unlikely to be very effective, estimates are inflated.

-The virus is going to evolve much faster than you expect it to. It’s very good at recombining itself. It’s also easy for it to just copy genes or delete genes. That’s what it did in Congo, it deleted a gene so it no longer shows up as positive in tests.

-And finally, when cases came crashing down, I warned you all:
Human beings don’t like to think about tail risks, because pointing out tail risks calls the obvious path forward into doubt. NATO is winning in Ukraine, a winning team in a war doesn’t like considering the implications of nuclear war. People who point out tail risks are party-poopers.
Monkeypox is similar. It’s the easy option to say “23 people have died, cases are crashing, this is a nothingburger” and you might even prove to be right, but Orthopox viruses have killed 300 million people in the previous century. There is a distinct chance that we are currently incubating something that’s in the process of becoming similar to smallpox.
This is not what anyone wants to hear. If I wanted to earn the substack bucks, I would have to tell you it’s all fear mongering and Klaus Schwab wants to stop you from eating monkeys, or I would have to somehow blame Bill Gates for all of it.

Well, those were two potentially useful years. Two years to actually get prepared, to do something about the problem.

And again, when everyone had forgotten about it, in January 2023, I TOLD YOU:
The WHO was entirely right to declare this a global emergency. With situations like this, you’d rather anticipate what’s going to happen, than to end up responding to it. You know you did it right, when after it’s over people say: “What was all this panic needed for?”
The reason smallpox was eradicated is because the Americans did the math and realized it’s just cheaper to eradicate the virus than to have to be constantly on the lookout for it and keep vaccinating everyone. So far, it remains the only virus we have ever truly eradicated from human beings.
It’s possible for us to add monkeypox to the list of viruses eradicated from our species. Unfortunately, that’s not the direction things seem to be going. Cases have been steady for a month now, while the death toll creeps up.
My experience in life tells me that you should never ignore the power of human stupidity. This looks like the sort of thing where people only realize it’s a problem by the time it can no longer be solved, until which time it’s a “lamestream media fearmongering hoax” in the words of low status white males. My suggestion is to avoid that outcome. Developed nations should take a serious effort, to help nations where this virus still circulates eradicate it.
If you have the opportunity to eradicate a virus that causes your face to slowly rot off, you should probably take it.
And of course, the response I got here was:
Perhaps you could instead revisit Monkeypox. It appears by all measures that it’s completely fizzled out in contradiction to your fears that it would destroy the entire world.
In April of this year, I told you:

This is still spreading around the globe, but we now have an additional second version spreading in Congo that kills about 10% of people it infects. We’re basically just witnessing the rebirth of smallpox, but the system does not have the time and energy left to stop it.

So again, I’m going to tell you:

I have tried warning people for two years. Nothing was done.

You people can tell me what’s a useful way for me to spend my days:
  1. Operating the counter at a gas station during the night shift somewhere, because I have autism and no college degree (I would rather jump off a bridge than have to do a group project with blonde women ever again) and can’t wake up in the morning, so this is the station in life humanity has reserved for me.
  2. Pointing out that we’re witnessing the slow-motion rebirth of smallpox, but people fool themselves into thinking it’s a minor gay STD.
Well, I tried option two, everyone laughed at me and told me I was wrong.

But here’s what we’re now dealing with:

1africa.jpg


You know what that is? Exponential growth. And as the case fatality rate is climbing since week 26, it looks like they’re missing a growing share of cases.

You morons are now going to start vaccinating people in Congo, when you have a total of 230,000 vaccines available for them, on a population of 90 million.

You know you could have started half a year ago with this, right?

You know viruses evolve in response to vaccines right?

You realize most cases in gay men of monkeypox are now breakthrough infections, right, because the vaccines stop working?

You realize that when you start vaccinating in Congo, you’re going to start vaccinating people who are already infected, so you’re just going to draw their T cells into their arm, instead of where the body needs them, right? That could have the effect of making those people even sicker.

You realize nobody has any idea how effective these vaccines are against this clade, right?

You’re supposed to vaccinate people, BEFORE they are exposed to a virus, not in the middle of that virus circulating.

It takes months, before an IgG antibody response has matured. Until that time, it just selects for antibody resistant mutations.

You realize it already jumped into Rwanda, Uganda, Burundi and the Central African Republic by now, right?

The Central African Republic is in the middle of a civil war. Good luck vaccinating there, with your vaccines that need to be kept at freezing temperatures.

It’s not my fault, I tried warning people. I was not allowed to use my account on Twitter until I deleted my tweets, everyone laughed at me, nobody took me seriously, they all said I was wrong.

As I told you, there was a window of opportunity. That window of opportunity has now in all likelihood closed, so now we have a virus that causes disfiguring sores on people’s genitals and kills children.

So forgive me, for just spending my days vaping cannabis, listening to midwest emo and watching horror movies. I think I deserve it.
 

helen

Panic Sex Lady
Last edited:

helen

Panic Sex Lady

21 Days Quarantine, Mandatory Test: Bengaluru Airport On High Alert Amid Mpox Outbreak​

Mpox In India: Pandemic like situation at Bengaluru International Airport as authorities implement strict Mpox containment rules - 21 days quarantine and mandatory test reports for all International passengers.​



 

helen

Panic Sex Lady
No comment.

Mpox: No Plan To Impose Travel Restrictions On Africans – US

Mpox: No Plan To Impose Travel Restrictions On Africans – US
thewillnews.com
FacebookTwitterLinkedInEmailCopy LinkWhatsAppShare
September 17, (THEWILL) – The United States has denied plans to impose travel restrictions on individuals arriving from African countries due to the rising cases of monkeypox (mpox).

John Nkengasong, the US Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, clarified this position during an online press briefing on Monday.

“The U.S. does not plan to put in place travel restrictions for people travelling from Africa. That is a rumour. So, we do not, at this point, think that is going to happen,” said Nkengasong.

The clarification came amid concerns that the US might reinstate travel policies like those introduced during the COVID-19 pandemic, including mandatory vaccinations for travellers.

Nkengasong said the United States would continue to work with the Africa Centres for Disease Control and Prevention (Africa CDC) and the WHO to ensure the spread of lethal outbreaks of mpox in Africa did not develop into a pandemic. He also promised an additional $35 million in support to fight mpox.

“The US is mobilising additional resources. The United States Agency for International Development (USAID) just announced $35 million, and we will stay committed until we bring this outbreak under control, in collaboration, of course, with others: WHO and Africa CDC,” he stated.

Mpox was first identified more than 50 years ago in the Democratic Republic of Congo (DRC). While the global spread started in 2022, a new version of the virus, one that is sexually transmissible, was identified in 2023 in Congo which housed over 21,000 suspected mpox cases, and 700 deaths just in 2024.

WHO Director-General, Dr. Tedros Ghebreyesus declared mpox a public health emergency of international concern in August 2024. The global health agency, on Friday, authorised the use of Bavarian Nordic MVA-BN vaccine for the treatment of Mpox.

Current data indicate that the vaccine is 76 percent effective after a single dose and 82 percent effective after two doses. However, WHO emphasised the need for continued data collection on the vaccine’s safety and effectiveness.
 

helen

Panic Sex Lady
Army researchers contribute to the development of promising mpox vaccine
By Quentin JohnsonSeptember 20, 2024

FORT DETRICK, Md. — Research conducted by U.S. Army Medical Research Institute of Infectious Diseases scientists into a promising mpox vaccine has been featured in the prestigious scientific journal Cell, highlighting the institute’s commitment to protecting Warfighters against emerging deadly diseases.

USAMRIID’s team contributed to the design of the study, conducted the animal model studies and performed the immunoassay work, according to Dr. Jay W. Hooper, USAMRIID’s chief of molecular virology and a senior author of the article, “Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates” published in the Sept. 4, 2024, issue of Cell.

The publication of the study findings is timely, as mpox continues to spread globally. More than 100,000 confirmed cases of mpox, including hundreds of deaths, have been reported across more than 120 countries from 2022 through mid-2024, according to the World Health Organization.

The study shows that while the mpox vaccine currently in use is effective, it has issues with cross-protection against similar viruses, incomplete immunity from mpox and adverse reactions. The new vaccine candidate, mRNA-1769, developed by Moderna, promises to address these shortcomings by using messenger RNA, or mRNA, to provide a more effective targeted approach to treating the disease.

“With the mRNA technology, we're able to produce a vaccine that gives quite potent responses with a very tolerable safety profile,” said Hooper, during an August 2024 interview with Cell Press.

The study found that mRNA-1769 lessened the symptoms and duration of the disease in animal models. This effectiveness means mpox patients could potentially see fewer symptoms such as less weight loss and lesions, according to the study.
The results also showed less viral shedding — spreading of the copied virus — in the blood and respiratory tract, which was a highlight of the study for Hooper.

“The most interesting finding was we confirmed what we had seen earlier with a DNA vaccine targeting mpox, and its protection against shedding of the virus from the throat swabs, which we have not seen with the MVA-based vaccines,” said Hooper.
Mpox is part of a larger group of viruses called orthopoxviruses, which includes smallpox and cowpox. The study found that mRNA-1769 has the potential to protect against those as well, a feature called cross-immunity, said co-first author Alec Freyn, a virology researcher at Moderna, during an August 2024 interview with Cell Press.

Cross-immunity is a key factor as it aligns with USAMRIID’s mission to defend against current and emerging biological threat agents for the protection of our Service Members, families and the nation.

“Improved orthopoxvirus vaccines are needed to strengthen our defenses against the threat posed by these viruses,” said Hooper.

As for future work and studies, Hooper said, the institute has done a lot of work with DNA vaccines against viruses of importance to the U.S. military and combining their strong preclinical expertise with the mRNA platform experience of the current industry could accelerate the development of vaccines for the Service Members.

Moderna’s mRNA-1769 vaccine is currently being assessed in a phase 1/2 clinical trial (NCT05995275) to address the safety and immunogenicity of an mRNA-based orthopoxvirus vaccine.
###
Collaborate with USAMRIID
Reference:
Cell, Mucker, Freyn, and Bixler et al., “Comparison of protection against Mpox following mRNA-1769 or MVA vaccination in NHPs” https://www.cell.com/cell/fulltext/S0092-8674(24)00972-3
Disclaimer:
Animal Care and Use Statement: The study mentioned in the article was carried out in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011 and The United States Army Medical Research Institute of Infectious Diseases Institutional Animal Care and Use Committee. The protocol was approved by the United States Army of Medical Research Institute of Infectious Diseases under an Institutional Animal Care and Use Committee in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to animals and experiments involving animals. The facility where this research was conducted is accredited by the AAALACi.

 

Heliobas Disciple

TB Fanatic
(fair use applies)


Genomic recombination causing rapid evolution of Mpox clade 1b, diverging into four lineages and 14 subgroups
Nikhil Prasad Fact checked by:Thailand Medical News Team
Sep 21, 2024

In the midst of ongoing global health concerns, scientists have uncovered alarming new developments surrounding the Mpox (Monkeypox) virus, specifically Clade 1b. A recent study, conducted by researchers from various international institutions, reveals that this particular strain of the virus is evolving at a rapid rate due to an unusually high frequency of genomic recombination. The virus has not only diverged into four distinct lineages but has also formed 14 subgroups based on tandem repeat (TR) polymorphisms. This rapid evolution raises concerns about the potential emergence of more lethal variants if action is not taken swiftly.

The researchers involved in this study are from several prestigious institutions, including Auxergen Inc., Rita Rossi Colwell Center in Baltimore, USA; Auxergen S.r.l., Tecnopolis PST, University of Bari in Italy; and Kaohsiung Municipal United Hospital in Taiwan. Their collaborative work has highlighted the significance of these findings in understanding the 2024 outbreak of Mpox and addressing the growing threat it poses to global public health.

This Medical News report delves deeper into the findings of this crucial research, shedding light on how genomic recombination is accelerating the evolution of Mpox Clade 1b and what this means for public health efforts worldwide.


Mpox Virus Clade 1b: A Public Health Emergency
On August 14, 2024, the World Health Organization (WHO) declared the Mpox virus Clade 1b outbreak a public health emergency of international concern. At that time, 18,737 cases and 541 deaths across 14 countries had been reported, with a fatality rate of approximately 3%. According to the European Centre for Disease Prevention and Control (ECDC), the actual number of cases is likely higher due to underreporting and under-ascertainment in certain regions.

Mpox Clade 1b is diverging at a much faster rate than Clade 2b, the strain that was primarily responsible for the 2022 outbreak. The accelerated divergence is attributed to a significant increase in genomic recombination, which is when segments of the virus’s genetic material are exchanged between different viral strains, leading to new variants.

The study revealed that the rate of recombination in Mpox Clade 1b is nearly twice that of Clade 2b, which had 11 subgroups. The findings show that this particular strain has already evolved into four separate lineages and 14 subgroups. This suggests that the virus is undergoing more frequent mutations and recombinations, making it more difficult to predict its future behavior and the potential impact on the affected populations.


Genomic Recombination: Fueling the Evolution of Mpox
One of the key factors contributing to the rapid evolution of Mpox Clade 1b is genomic recombination, a process where genetic material is exchanged between two or more viral strains. This exchange results in the creation of new viral variants, which can sometimes exhibit different characteristics, such as increased transmissibility, resistance to treatments, or heightened virulence.

Researchers used genomic sequences from 32 Mpox Clade 1b samples collected between October 2023 and August 2024 to conduct their analysis. They found that the tandem repeats in the genome of Clade 1b are mutating at a significantly higher frequency compared to Clade 2b, which dominated the 2022 outbreak. These tandem repeats play a crucial role in the structural integrity of the virus’s genome and its ability to replicate within host cells.

Through their phylogenetic analysis, the team identified four distinct lineages within Mpox Clade 1b. Each lineage has evolved into various subgroups, forming a total of 14 subgroups based on nine tandem repeat polymorphisms. The presence of these subgroups indicates that the virus is continuously evolving, with new variants emerging over time.

The study also highlighted that linkage disequilibrium (LD) analysis uncovered 10 independent recombination clusters among all four lineages. Recombination rates in Clade 1b were found to be substantially higher than in Clade 2b, with incidences of superinfection - where a single host is infected with multiple strains of the virus - playing a key role in the ongoing recombination of the virus.


Potential Public Health Implications
The findings from this study raise significant concerns about the potential for more lethal Mpox strains to emerge. The accelerated recombination and mutation rates seen in Clade 1b make it difficult to predict how the virus will evolve in the future. Without timely intervention, there is a risk that new variants may arise with greater pathogenicity, leading to higher morbidity and mortality rates.

In regions where laboratory capacity is limited, particularly in parts of Africa, the ability to detect and track new Mpox cases is hindered. This lack of surveillance means that the true extent of the virus’s evolution may be underestimated. The researchers emphasize the need for increased genomic surveillance and more transparent sharing of viral sequences in order to better understand the scope of the outbreak and take appropriate measures to contain it.

It has also been shown that poxvirus recombinants can emerge from virus-by-virus crosses within the same genus. This suggests that further recombination events could lead to the development of new strains with altered characteristics, potentially exacerbating the global outbreak.


Study Findings and Conclusion

The study’s findings underscore the urgency of addressing the rapid evolution of Mpox Clade 1b. The emergence of four lineages and 14 subgroups is a clear indication that the virus is evolving at a rate faster than previously observed in the 2022 outbreak of Clade 2b. With recombination rates doubling and superinfections contributing to the ongoing evolution of the virus, public health officials must act quickly to prevent the spread of more dangerous variants.

The study concluded that genomic surveillance and transparent sharing of Mpox sequences across affected regions are critical to understanding the virus’s evolution. By monitoring the virus more closely, scientists can provide better insights into the outbreak and develop strategies to mitigate its impact on global health. The continued evolution of the virus poses a significant threat, and the development of new recombinant variants could result in increased transmissibility or higher mortality rates. Prompt action is essential to avoid the emergence of more virulent strains.

The study findings were published on a preprint server and are currently being peer reviewed,

 

helen

Panic Sex Lady
(fair use applies)


Genomic recombination causing rapid evolution of Mpox clade 1b, diverging into four lineages and 14 subgroups
Nikhil Prasad Fact checked by:Thailand Medical News Team
Sep 21, 2024

In the midst of ongoing global health concerns, scientists have uncovered alarming new developments surrounding the Mpox (Monkeypox) virus, specifically Clade 1b. A recent study, conducted by researchers from various international institutions, reveals that this particular strain of the virus is evolving at a rapid rate due to an unusually high frequency of genomic recombination. The virus has not only diverged into four distinct lineages but has also formed 14 subgroups based on tandem repeat (TR) polymorphisms. This rapid evolution raises concerns about the potential emergence of more lethal variants if action is not taken swiftly.

The researchers involved in this study are from several prestigious institutions, including Auxergen Inc., Rita Rossi Colwell Center in Baltimore, USA; Auxergen S.r.l., Tecnopolis PST, University of Bari in Italy; and Kaohsiung Municipal United Hospital in Taiwan. Their collaborative work has highlighted the significance of these findings in understanding the 2024 outbreak of Mpox and addressing the growing threat it poses to global public health.

This Medical News report delves deeper into the findings of this crucial research, shedding light on how genomic recombination is accelerating the evolution of Mpox Clade 1b and what this means for public health efforts worldwide.


Mpox Virus Clade 1b: A Public Health Emergency
On August 14, 2024, the World Health Organization (WHO) declared the Mpox virus Clade 1b outbreak a public health emergency of international concern. At that time, 18,737 cases and 541 deaths across 14 countries had been reported, with a fatality rate of approximately 3%. According to the European Centre for Disease Prevention and Control (ECDC), the actual number of cases is likely higher due to underreporting and under-ascertainment in certain regions.

Mpox Clade 1b is diverging at a much faster rate than Clade 2b, the strain that was primarily responsible for the 2022 outbreak. The accelerated divergence is attributed to a significant increase in genomic recombination, which is when segments of the virus’s genetic material are exchanged between different viral strains, leading to new variants.

The study revealed that the rate of recombination in Mpox Clade 1b is nearly twice that of Clade 2b, which had 11 subgroups. The findings show that this particular strain has already evolved into four separate lineages and 14 subgroups. This suggests that the virus is undergoing more frequent mutations and recombinations, making it more difficult to predict its future behavior and the potential impact on the affected populations.


Genomic Recombination: Fueling the Evolution of Mpox
One of the key factors contributing to the rapid evolution of Mpox Clade 1b is genomic recombination, a process where genetic material is exchanged between two or more viral strains. This exchange results in the creation of new viral variants, which can sometimes exhibit different characteristics, such as increased transmissibility, resistance to treatments, or heightened virulence.

Researchers used genomic sequences from 32 Mpox Clade 1b samples collected between October 2023 and August 2024 to conduct their analysis. They found that the tandem repeats in the genome of Clade 1b are mutating at a significantly higher frequency compared to Clade 2b, which dominated the 2022 outbreak. These tandem repeats play a crucial role in the structural integrity of the virus’s genome and its ability to replicate within host cells.

Through their phylogenetic analysis, the team identified four distinct lineages within Mpox Clade 1b. Each lineage has evolved into various subgroups, forming a total of 14 subgroups based on nine tandem repeat polymorphisms. The presence of these subgroups indicates that the virus is continuously evolving, with new variants emerging over time.

The study also highlighted that linkage disequilibrium (LD) analysis uncovered 10 independent recombination clusters among all four lineages. Recombination rates in Clade 1b were found to be substantially higher than in Clade 2b, with incidences of superinfection - where a single host is infected with multiple strains of the virus - playing a key role in the ongoing recombination of the virus.


Potential Public Health Implications
The findings from this study raise significant concerns about the potential for more lethal Mpox strains to emerge. The accelerated recombination and mutation rates seen in Clade 1b make it difficult to predict how the virus will evolve in the future. Without timely intervention, there is a risk that new variants may arise with greater pathogenicity, leading to higher morbidity and mortality rates.

In regions where laboratory capacity is limited, particularly in parts of Africa, the ability to detect and track new Mpox cases is hindered. This lack of surveillance means that the true extent of the virus’s evolution may be underestimated. The researchers emphasize the need for increased genomic surveillance and more transparent sharing of viral sequences in order to better understand the scope of the outbreak and take appropriate measures to contain it.

It has also been shown that poxvirus recombinants can emerge from virus-by-virus crosses within the same genus. This suggests that further recombination events could lead to the development of new strains with altered characteristics, potentially exacerbating the global outbreak.


Study Findings and Conclusion
The study’s findings underscore the urgency of addressing the rapid evolution of Mpox Clade 1b. The emergence of four lineages and 14 subgroups is a clear indication that the virus is evolving at a rate faster than previously observed in the 2022 outbreak of Clade 2b. With recombination rates doubling and superinfections contributing to the ongoing evolution of the virus, public health officials must act quickly to prevent the spread of more dangerous variants.

The study concluded that genomic surveillance and transparent sharing of Mpox sequences across affected regions are critical to understanding the virus’s evolution. By monitoring the virus more closely, scientists can provide better insights into the outbreak and develop strategies to mitigate its impact on global health. The continued evolution of the virus poses a significant threat, and the development of new recombinant variants could result in increased transmissibility or higher mortality rates. Prompt action is essential to avoid the emergence of more virulent strains.

The study findings were published on a preprint server and are currently being peer reviewed,

Gain of function.
 

night driver

ESFP adrift in INTJ sea
Does anyone know if Doctor Niman is still around and has he done ANYTHING with MPOX??

I didn't see ANYTHING from his RECOMBINOMICS shop on MPOX.
 
Top